Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14582767 | 0.84 | NPSR1 (0.59) | NPSR1KDM4CKDM4ESTAT3HIF1A | |
| SCHEMBL23925907 | 0.75 | NPSR1 (0.48) | NPSR1KDM4CKDM4ESTAT3HIF1A | |
| SCHEMBL18990911 | 0.75 | NPSR1 (0.48) | NPSR1KDM4CKDM4ESTAT3HIF1A | |
| SCHEMBL4115514 | 0.75 | KDM4E (0.49) | NPSR1KDM4CKDM4ESTAT3HIF1A | |
| SCHEMBL14891967 | 0.69 | PLAU (0.53) | NPSR1KDM4CKDM4EMAPTHSD17B10 | |
| SCHEMBL18529020 | 0.68 | NPSR1 (0.50) | NPSR1KDM4CKDM4EHSD17B10KMT2A | |
| SCHEMBL2632700 | 0.68 | NPSR1 (0.50) | NPSR1KDM4CKDM4EMAPTHSD17B10 | |
| SCHEMBL20028494 | 0.67 | SMN1; SMN2 (0.58) | KDM4ESTAT3HIF1ALMNAMAPT | |
| SCHEMBL28613328 | 0.67 | NPSR1 (0.43) | NPSR1KDM4CKDM4ESTAT3HIF1A | |
| SCHEMBL25290051 | 0.67 | NPSR1 (0.54) | NPSR1KDM4CKDM4EMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083708-A1 | IL-17 MODULATORS AND USES THEREOF | NNOCARE PHARMA INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4402138-B1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025119326-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2025-06-12 | — | — | WO | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2024-10-24 | — | — | US | disclosed |
| WO-2024212941-A1 | CBL-B INHIBITOR | 北京诺诚健华医药科技有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-12115157-B2 | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-10-15 | — | — | US | disclosed |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-20180258102-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2018-09-13 | — | — | US | disclosed |
| EP-3324977-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| WO-2017015449-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-5326776-A | Tetrazoles | ABBOTT LABORATORIES (US) | 1994-07-05 | — | — | US | disclosed |
| WO-1993017681-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | NPSR1 114/4885KDM4C 1740/4885KDM4E 1198/4885 |
| US-12115157-B2 | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament | GPR52, GPR88, GPR68 | NPSR1 136/4885KDM4C 3091/4885KDM4E 2658/4885 |
| US-20260083708-A1 | IL-17 MODULATORS AND USES THEREOF | IL17A, IL2, IL23R | NPSR1 662/4885KDM4C 3036/4885KDM4E 3125/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | NPSR1 114/4885KDM4C 1740/4885KDM4E 1198/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | NPSR1 2051/4885KDM4C 4501/4885KDM4E 4059/4885 |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | NPSR1 114/4885KDM4C 1740/4885KDM4E 1198/4885 |
| US-20180258102-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | NPSR1 114/4885KDM4C 1740/4885KDM4E 1198/4885 |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | NPSR1 4365/4885KDM4C 1204/4885KDM4E 1505/4885 |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | NPSR1 4470/4885KDM4C 1272/4885KDM4E 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.